NCT03683433View on ClinicalTrials.gov

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

September 20, 2027

Study Completion Date

September 20, 2027

Conditions

Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaChronic Myelomonocytic LeukemiaIDH2 Gene MutationMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given SC or IV

DRUG

Enasidenib Mesylate

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER